Cargando…
Metabolomics of Multimorbidity: Could It Be the Quo Vadis?
Multimorbidity, the simultaneous presence of two or more chronic diseases, affects the health care to a great extent. Its association with health care cost, more disability, and poor quality of life makes it a major public health risk. The matter of worry is that management of a multimorbid conditio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962190/ https://www.ncbi.nlm.nih.gov/pubmed/35359598 http://dx.doi.org/10.3389/fmolb.2022.848971 |
_version_ | 1784677744194355200 |
---|---|
author | Dash, Pujarini Mohapatra, Soumya R. Pati, Sanghamitra |
author_facet | Dash, Pujarini Mohapatra, Soumya R. Pati, Sanghamitra |
author_sort | Dash, Pujarini |
collection | PubMed |
description | Multimorbidity, the simultaneous presence of two or more chronic diseases, affects the health care to a great extent. Its association with health care cost, more disability, and poor quality of life makes it a major public health risk. The matter of worry is that management of a multimorbid condition is complicated by the fact that multiple types of treatment may be required to treat different diseases at a time, and the interaction between some of the therapies can be detrimental. Understanding the causal factors of simultaneously occurring disease conditions and investigating the connected pathways involved in the whole process may resolve the complication. When different disease conditions present in an individual share common responsible factors, treatment strategies targeting at those common causes will certainly reduce the chance of development of multimorbidity occurring because of those factors. Metabolomics that can dig out the underlying metabolites/molecules of a medical condition is believed to be an effective technique for identification of biomarkers and intervention of effective treatment strategies for multiple diseases. We hypothesize that understanding the metabolic profile may shed light on targeting the common culprit for different/similar chronic diseases ultimately making the treatment strategy more effective with a combinatorial effect. |
format | Online Article Text |
id | pubmed-8962190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89621902022-03-30 Metabolomics of Multimorbidity: Could It Be the Quo Vadis? Dash, Pujarini Mohapatra, Soumya R. Pati, Sanghamitra Front Mol Biosci Molecular Biosciences Multimorbidity, the simultaneous presence of two or more chronic diseases, affects the health care to a great extent. Its association with health care cost, more disability, and poor quality of life makes it a major public health risk. The matter of worry is that management of a multimorbid condition is complicated by the fact that multiple types of treatment may be required to treat different diseases at a time, and the interaction between some of the therapies can be detrimental. Understanding the causal factors of simultaneously occurring disease conditions and investigating the connected pathways involved in the whole process may resolve the complication. When different disease conditions present in an individual share common responsible factors, treatment strategies targeting at those common causes will certainly reduce the chance of development of multimorbidity occurring because of those factors. Metabolomics that can dig out the underlying metabolites/molecules of a medical condition is believed to be an effective technique for identification of biomarkers and intervention of effective treatment strategies for multiple diseases. We hypothesize that understanding the metabolic profile may shed light on targeting the common culprit for different/similar chronic diseases ultimately making the treatment strategy more effective with a combinatorial effect. Frontiers Media S.A. 2022-03-11 /pmc/articles/PMC8962190/ /pubmed/35359598 http://dx.doi.org/10.3389/fmolb.2022.848971 Text en Copyright © 2022 Dash, Mohapatra and Pati. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Dash, Pujarini Mohapatra, Soumya R. Pati, Sanghamitra Metabolomics of Multimorbidity: Could It Be the Quo Vadis? |
title | Metabolomics of Multimorbidity: Could It Be the Quo Vadis? |
title_full | Metabolomics of Multimorbidity: Could It Be the Quo Vadis? |
title_fullStr | Metabolomics of Multimorbidity: Could It Be the Quo Vadis? |
title_full_unstemmed | Metabolomics of Multimorbidity: Could It Be the Quo Vadis? |
title_short | Metabolomics of Multimorbidity: Could It Be the Quo Vadis? |
title_sort | metabolomics of multimorbidity: could it be the quo vadis? |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962190/ https://www.ncbi.nlm.nih.gov/pubmed/35359598 http://dx.doi.org/10.3389/fmolb.2022.848971 |
work_keys_str_mv | AT dashpujarini metabolomicsofmultimorbiditycoulditbethequovadis AT mohapatrasoumyar metabolomicsofmultimorbiditycoulditbethequovadis AT patisanghamitra metabolomicsofmultimorbiditycoulditbethequovadis |